“There is a lot of excitement surrounding some of these novel agents, a lot of work being done in improving the quality of patients’ lives, and a lot of work being done to find new ways to detect disease when it is still at an early stage or to prevent it,” Wadlow said. Read more . . .
While the use of combination chemotherapies has served to improve outcomes for patients with metastatic pancreatic cancer, new research examining novel agents like devimistat (formerly CPI-613) could continue to move the needle forward, according to Raymond Wadlow, MD.